Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

12 Dec 2024

Abstract excerpt

Background: Osteosarcoma is a rare disease, but it is the most frequent malignant bone tumor. Primary treatment consists of preoperative MAP (methotrexate (MTX), doxorubicin and cisplatin) chemotherapy followed by surgery and adjuvant chemotherapy. Pathological response to preoperative chemotherapy is one of the most important prognostic factors, but molecular biomarkers are lacking. Additionally,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Drug Transport and Resistance Mechanisms
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39771563
DOI: 10.3390/pharmaceutics16121585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 ProtocolPMID 39771563Read ↗

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Semantic proximity Read ↗

The role of pharmacogenetics in the treatment of osteosarcomaSemantic proximity Read ↗

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review of 2010-2020Semantic proximity Read ↗

Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Semantic proximity Read ↗

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.Semantic proximity Read ↗

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.Semantic proximity Read ↗

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcomaSemantic proximity Read ↗

A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.Semantic proximity Read ↗

Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.Semantic proximity Read ↗

Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Semantic proximity Read ↗

Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.Semantic proximity Read ↗

Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.